Axion BioSystems Acquires High-Throughput, High-Density CMOS MEA Technology from CytoTronics

Audio By Carbonatix

ATLANTA--(BUSINESS WIRE)--Jan 22, 2026--

Axion BioSystems, a leading life sciences tools company focused on cutting-edge live-cell bioelectronic assay and imaging systems, announces the acquisition of the intellectual property and assets of CytoTronics, Inc. The purchase brings novel high-density (HD) electrode array technology developed at Harvard University to Axion’s growing product suite and strengthens Axion’s ability to provide researchers with the most advanced tools for disease research and drug discovery.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113011268/en/

Next-generation CMOS MEA chip technology acquired by Axion BioSystems integrates over 13 million nanoscale multimodal electrode-based sensors distributed across industry-standard 96- or 384-well microplates, enabling high-throughput, single-cell–level functional screening for disease research and drug discovery.

Bioelectronic assays use biocompatible electronic microsensors embedded in the cell culture surface to continuously monitor living cells, detecting cell number, morphology, and even neural firing and cardiac beating without additional labels or dyes.

CytoTronics’ next-generation CMOS (Complementary Metal–Oxide–Semiconductor) microelectrode array (MEA) plates contain over 13 million nanoscale multimodal electrode-based sensors distributed across industry-standard 96- or 384-well microplates, enabling high-throughput screening for drug discovery at unprecedented single-cell resolution.

Co-founder and former Chief Executive Officer of CytoTronics, Inc., Jeffrey Abbott, PhD, now Vice President at Axion BioSystems, said: “Axion has a long-standing reputation for delivering intuitive, reliable, and scalable electrophysiology platforms to the cell biology community. That industry leadership makes Axion the ideal home for CytoTronics’ innovative technology. I’m excited to work with the Axion team to commercialize the next generation of high-throughput, high-density CMOS MEA assays for neural and cardiac drug discovery.”

“Since its founding in 2008, Axion’s goal has been to provide scientists with best-in-class tools to study electrically active cells like neurons and cardiomyocytes,” said Julien Bradley, Chief Executive Officer at Axion BioSystems. “The acquisition of CytoTronics’ technology is highly strategic for Axion, complementing our industry-leading MEA and impedance platforms with high-density arrays without sacrificing high throughput, and leveraging our high-performance software, robust hardware, and customer support infrastructure.”

About Axion BioSystems

Axion BioSystems is a leading life sciences tools company focused on innovative live-cell assays used to study the function of cells in vitro for drug discovery and disease modeling. The team at Axion BioSystems is dedicated to continuing the advancement of new technologies that accelerate research and further the understanding of biological complexity outside of the body. Axion BioSystems is headquartered in Atlanta, Georgia, USA, and has offices in the Netherlands, the UK, and China.

www.axionbiosystems.com

View source version on businesswire.com:https://www.businesswire.com/news/home/20260113011268/en/

CONTACT: Mike Clements

SVP Scientific Partnerships & Strategy

+1-678-469-3439

[email protected]

KEYWORD: GEORGIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: RESEARCH NEUROLOGY CARDIOLOGY BIOTECHNOLOGY RADIOLOGY HEALTH PHARMACEUTICAL OTHER SCIENCE SCIENCE

SOURCE: Axion BioSystems

Copyright Business Wire 2026.

PUB: 01/22/2026 08:00 AM/DISC: 01/22/2026 08:00 AM

http://www.businesswire.com/news/home/20260113011268/en